Enveric Biosciences, Inc. (ENVB) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
4851 TAMIAMI TRAIL N, SUITE 200 NAPLES, FL 34103 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 17,724 | 17,356 | 1,578 | 431 | 1,371 | 4,882 | |||
| Cash and cash equivalents | 17,724 | 17,356 | 1,578 | 431 | 1,371 | 4,882 | |||
| Receivables | 6,384 | 7,871 | 8,838 | ||||||
| Prepaid expense | |||||||||
| Deferred costs | |||||||||
| Other current assets | 784 | 819 | 924 | ||||||
| Other undisclosed current assets | 708 | 381 | 701 | ||||||
| Total current assets: | 18,432 | 17,737 | 2,279 | 7,599 | 10,061 | 14,645 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 64 | 176 | ✕ | ✕ | |||||
| Property, plant and equipment | 677 | 294 | 83 | 59 | 95 | ||||
| Intangible assets, net (including goodwill) | (9,332) | 8,512 | 1,818 | 17,314 | 19,508 | 31,368 | |||
| Goodwill | (9,712) | 1,588 | 13,730 | 13,730 | 21,898 | ||||
| Intangible assets, net (excluding goodwill) | 380 | 6,924 | 1,818 | 3,584 | 5,778 | 9,470 | |||
| Deferred income tax assets | 9 | ✕ | ✕ | ||||||
| Other undisclosed noncurrent assets | 9,712 | 9 | 6,089 | ||||||
| Total noncurrent assets: | 1,121 | 8,982 | 1,818 | 17,406 | 19,576 | 37,552 | |||
| TOTAL ASSETS: | 19,553 | 26,719 | 4,097 | 25,005 | 29,637 | 52,197 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 2,169 | 1,293 | 1,990 | 1,698 | 2,583 | ||||
| Interest and dividends payable | ✕ | ✕ | 219 | 172 | 263 | ||||
| Taxes payable | ✕ | ✕ | 648 | 182 | 447 | ||||
| Employee-related liabilities | ✕ | ✕ | 738 | 950 | 1,157 | ||||
| Accounts payable | 463 | ||||||||
| Accrued liabilities | 1,706 | 1,293 | 149 | 109 | 329 | ||||
| Other undisclosed accounts payable and accrued liabilities | 236 | 283 | 388 | ||||||
| Debt | 8,762 | 5,214 | 5,552 | ||||||
| Derivative instruments and hedges, liabilities | 727 | ||||||||
| Other liabilities | 851 | ||||||||
| Other undisclosed current liabilities | 249 | 791 | 3,632 | 7,778 | 22,233 | ||||
| Total current liabilities: | 3,996 | 2,084 | 14,384 | 14,689 | 30,368 | ||||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 69 | 1,131 | |||||||
| Long-term debt, excluding current maturities | 1,131 | ||||||||
| Operating lease, liability | 69 | ✕ | ✕ | ||||||
| Other undisclosed noncurrent liabilities | 2,192 | 4,189 | 1,250 | ||||||
| Total noncurrent liabilities: | 2,330 | 4,189 | 2,381 | ||||||
| Other undisclosed liabilities | 681 | ||||||||
| Total liabilities: | 3,996 | 4,413 | 681 | 14,384 | 18,878 | 32,748 | |||
| Temporary equity, carrying amount | 885 | ||||||||
| Equity | |||||||||
| Equity, attributable to parent | 14,672 | 22,306 | 3,416 | 10,622 | 10,759 | 19,448 | |||
| Preferred stock | 33 | 4 | 4 | 4 | |||||
| Common stock | 21 | 326 | 101 | 25 | 423 | 182 | |||
| Additional paid in capital | 94,396 | 82,747 | 15,223 | 51,040 | 44,723 | 34,223 | |||
| Accumulated other comprehensive income (loss) | (537) | (31) | (181) | 60 | 87 | 37 | |||
| Accumulated deficit | (79,208) | (60,736) | (11,760) | (40,508) | (34,478) | (14,998) | |||
| Stockholders' equity note, subscriptions receivable | |||||||||
| Total equity: | 14,672 | 22,306 | 3,416 | 10,622 | 10,759 | 19,448 | |||
| TOTAL LIABILITIES AND EQUITY: | 19,553 | 26,719 | 4,097 | 25,005 | 29,637 | 52,197 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 39,915 | 42,998 | 48,594 | |||||
| Cost of revenue | (31,764) | (34,015) | (38,356) | |||||
| Gross profit: | 8,151 | 8,984 | 10,238 | |||||
| Operating expenses | (27,415) | (64,623) | (5,617) | (14,476) | (16,130) | (22,208) | ||
| Operating loss: | (27,415) | (64,623) | (5,617) | (6,325) | (7,146) | (11,971) | ||
| Nonoperating income (expense) | 7,458 | 8,192 | 1,247 | 1,110 | (3,403) | 504 | ||
| Investment income, nonoperating | 3,473 | |||||||
| Interest and debt expense | (5) | (10) | (445) | (691) | (730) | (575) | ||
| Loss from continuing operations before equity method investments, income taxes: | (19,963) | (56,442) | (4,815) | (5,906) | (11,279) | (12,042) | ||
| Other undisclosed income from continuing operations before income taxes | 5 | 10 | 691 | 730 | 575 | |||
| Loss from continuing operations before income taxes: | (19,957) | (56,432) | (4,815) | (5,215) | (10,549) | (11,467) | ||
| Income tax expense (benefit) | 1,486 | 7,455 | (389) | (6,349) | 2,392 | |||
| Loss from continuing operations: | (18,471) | (48,977) | (4,815) | (5,604) | (16,898) | (9,075) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | (48,977) | (4,815) | (5,604) | (16,898) | (9,075) | |
| Net loss: | (18,471) | (48,977) | (4,815) | (5,604) | (16,898) | (9,075) | ||
| Other undisclosed net loss attributable to parent | (2,049) | |||||||
| Net loss attributable to parent: | (18,471) | (48,977) | (6,865) | (5,604) | (16,898) | (9,075) | ||
| Preferred stock dividends and other adjustments | (329) | (426) | (2,583) | (2,089) | ||||
| Net loss available to common stockholders, diluted: | (18,800) | (48,977) | (6,865) | (6,030) | (19,481) | (11,164) | ||
Comprehensive Income ($ in thousands)
| 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (18,471) | (48,977) | (4,815) | (5,604) | (16,898) | (9,075) | ||
| Other comprehensive income | 7,034 | |||||||
| Other undisclosed comprehensive loss | (453) | (2,533) | (2,045) | |||||
| Comprehensive income (loss): | (18,471) | (48,977) | 2,219 | (6,057) | (19,431) | (11,120) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | (835) | 150 | ||||||
| Comprehensive income (loss), net of tax, attributable to parent: | (19,306) | (48,826) | 2,219 | (6,057) | (19,431) | (11,120) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.